Literature DB >> 8476402

Group cognitive-behavioral treatment of panic disorder.

M J Telch1, J A Lucas, N B Schmidt, H H Hanna, T LaNae Jaimez, R A Lucas.   

Abstract

The present study examined the efficacy of an 8-wk, cognitive-behavioral group treatment for panic disorder. Patients meeting DSM-III-R criteria for panic disorder with or without agoraphobia were randomly assigned to treatment (N = 34) or delayed treatment control (N = 33). The treatment consisted of: (a) education and corrective information; (b) cognitive therapy; (c) training in diaphragmatic breathing; and (d) interoceptive exposure. At posttreatment, 85% of treated Ss were panic free, compared to 30% of controls. Treated Ss also showed clinically significant improvement on indices of anxiety, agoraphobia, depression and fear of fear. Recovery, as estimated conservatively by the attainment of normal levels of functioning on each of the major clinical dimensions of the disorder (i.e. panic, anxiety and avoidance), was achieved in 64% of the treated Ss and 9% of the controls. At the 6 month follow-up, 63% of the treated patients met criteria for recovery. These findings mirror those from recently-completed trials of individually-administered cognitive-behavioral treatment, and suggest that CBT is a viable alternative to pharmacotherapy in the treatment of panic disorder.

Entities:  

Mesh:

Year:  1993        PMID: 8476402     DOI: 10.1016/0005-7967(93)90026-q

Source DB:  PubMed          Journal:  Behav Res Ther        ISSN: 0005-7967


  19 in total

1.  Challenges and Successes in Dissemination of Evidence-Based Treatments for Posttraumatic Stress: Lessons Learned From Prolonged Exposure Therapy for PTSD.

Authors:  Edna B Foa; Seth J Gillihan; Richard A Bryant
Journal:  Psychol Sci Public Interest       Date:  2013-05

2.  The interactive role of anxiety sensitivity and pubertal status in predicting anxious responding to bodily sensations among adolescents.

Authors:  Ellen W Leen-Feldner; Laura E Reardon; Laura G McKee; Matthew T Feldner; Kimberly A Babson; Michael J J Zvolensky
Journal:  J Abnorm Child Psychol       Date:  2006-11-18

Review 3.  Coping skills and exposure therapy in panic disorder and agoraphobia: latest advances and future directions.

Authors:  Alicia E Meuret; Kate B Wolitzky-Taylor; Michael P Twohig; Michelle G Craske
Journal:  Behav Ther       Date:  2011-08-27

4.  Anxiety sensitivity risk reduction in smokers: A randomized control trial examining effects on panic.

Authors:  Norman B Schmidt; Amanda M Raines; Nicholas P Allan; Michael J Zvolensky
Journal:  Behav Res Ther       Date:  2015-12-21

Review 5.  Panic disorder.

Authors:  M H Rapaport; C Barrett
Journal:  Curr Psychiatry Rep       Date:  2001-08       Impact factor: 5.285

6.  Panic symptoms and elevated suicidal ideation and behaviors among trauma exposed individuals: Moderating effects of post-traumatic stress disorder.

Authors:  Brian J Albanese; Aaron M Norr; Daniel W Capron; Michael J Zvolensky; Norman B Schmidt
Journal:  Compr Psychiatry       Date:  2015-05-21       Impact factor: 3.735

Review 7.  Panic disorder.

Authors:  Shailesh Kumar; Darren Malone
Journal:  BMJ Clin Evid       Date:  2008-12-16

8.  Internet-versus group-administered cognitive behaviour therapy for panic disorder in a psychiatric setting: a randomised trial.

Authors:  Jan Bergström; Gerhard Andersson; Brjánn Ljótsson; Christian Rück; Sergej Andréewitch; Andreas Karlsson; Per Carlbring; Erik Andersson; Nils Lindefors
Journal:  BMC Psychiatry       Date:  2010-07-02       Impact factor: 3.630

Review 9.  Alcoholism: the role of different motivational systems.

Authors:  R O Pihl; J B Peterson
Journal:  J Psychiatry Neurosci       Date:  1995-11       Impact factor: 6.186

10.  Anxiety sensitivity as a predictor of the clinical course of panic disorder: a 1-year follow-up study.

Authors:  Carlos Israel Pérez Benítez; M Tracie Shea; Susan Raffa; Richard Rende; Ingrid R Dyck; Holly J Ramsawh; Maria Orlando Edelen; Martin B Keller
Journal:  Depress Anxiety       Date:  2009       Impact factor: 6.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.